Eleusis Benefit Corporation

Eleusis is a private life sciences company that studies and develops psychedelic drugs for therapeutic use. They accomplish this by understanding how to mitigate and manage their psychoactivity. One of their main areas of focus is the therapeutic use of psychedelic drugs in chronic inflammation.1

Recently, Eleusis completed a phase I clinical trial exploring the safety and tolerability of using LSD (lysergic acid diethylamide) in conjunction with therapy for treating Alzheimer’s disease.2

Eleusis was founded by Shlomi Raz who servers as Chairman and CEO. Dr. Charles D. Nichols, Professor of Pharmacology at the Louisiana State University Science Center, is Lead Scientist at Eleusis. Dr. Nichols pioneered research into the role of serotonin 5-HT2A receptors in chronic inflammation.3,4

  1. Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. International Review of Psychiatry. 2018;30(4):363-375. doi:10.1080/09540261.2018.1481827
  2. Family N, Maillet EL, Williams LTJ, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology. December 2019. doi:10.1007/s00213-019-05417-7
  3. Flanagan TW, Sebastian MN, Battaglia DM, Foster TP, Maillet EL, Nichols CD. Activation of 5-HT 2 Receptors Reduces Inflammation in Vascular Tissue and Cholesterol Levels in High-Fat Diet-Fed Apolipoprotein E Knockout Mice. Sci Rep. 2019;9(1):1-10. doi:10.1038/s41598-019-49987-0
  4. Flanagan TW, Sebastian MN, Battaglia DM, Foster TP, Cormier SA, Nichols CD. 5-HT2 receptor activation alleviates airway inflammation and structural remodeling in a chronic mouse asthma model. Life Sciences. 2019;236:116790. doi:10.1016/j.lfs.2019.116790